• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • English
    • Español (Spanish)
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Hide Search
Show Search
866.626.6847
  • About
    • Our Work
    • Our Team
    • Our Partners
  • Exposures
    • Pregnancy & Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
  • Studies
    • Ongoing Studies
    • Pregnant Women
    • Join Now
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Meetings
    • FAQs
    • OTIS Membership
  • Media
    • Press Releases
    • Media Requests
  • In Your Area
  • OTIS
    • About OTIS
    • OTIS Membership
    • Annual Meeting
    • Member Log-In
    • Donate
  • Contact

Labetalol

October 1, 2018

This sheet talks about exposure to labetalol in a pregnancy or while breastfeeding.  This information should not take the place of medical advice from your healthcare provider.

What is labetalol?

Labetalol, also known as Trandate®, Normodyne®, or Labrocol® is in a group of medications called beta-blockers. Labetalol is used to treat high blood pressure and chest pain. Labetalol works by slowing the heart rate and opening up blood vessels to improve blood flow and lower blood pressure.

How long does labetalol stay in the body? Should I stop taking it before I try to get pregnant?

Talk to your healthcare provider before making any changes to your medications.  People break down medications at different rates. In healthy adults, on average, it takes about two days for most of the labetalol to be gone from the body.

Can the use of labetalol cause a miscarriage?

No studies have been done to see if labetalol increases the chance of miscarriage when the medication is used in pregnancy.

Can taking labetalol in the first trimester cause a birth defect?

In every pregnancy, a woman starts out with a 3-5% chance of having a baby with a birth defect. This is called her background risk. The limited information looking at the use of labetalol during pregnancy does not suggest that it increases the chance to have a baby with a birth defect.

Can taking labetalol cause other pregnancy complications?

Maternal high blood pressure can increase pregnancy complications.  Most studies do not find that labetalol itself increases the chance for low birth weight, premature delivery, or stillbirth.

Can taking labetalol near delivery cause problems for the baby?

There have been a few reports of labetalol exposure in late pregnancy leading to an infant having temporary symptoms of beta-blockade. Beta-blockade symptoms are caused by a beta blocker being in the baby’s system. Symptoms include slowed heart rate and low blood sugar.

Will taking labetalol during pregnancy affect my baby’s behavior or cause learning problems?

One study of 32 children between the ages of 3-7 years old whose mothers took labetalol during pregnancy found no differences on formal testing of learning and behavior compared to children whose mothers did not take labetalol.  A second study found a higher chance for attention deficit hyperactivity disorder (ADHD) in children of mothers who took labetalol or a different type of high blood pressure medicine during pregnancy.  However, this is not good evidence for labetalol being the cause and suggests the role of high blood pressure should be looked at further.

I am breastfeeding, can I take labetalol?

Labetalol has been found only in small amounts in breastmilk. Because only a low amount enters breastmilk, it is compatible with breastfeeding. If you are worried about any symptoms that the baby has, contact the child’s healthcare provider.  Be sure to talk to your healthcare provider about all of your breastfeeding questions.*

What if the baby’s father takes labetalol?

In general, exposures that fathers have are unlikely to increase risks to a pregnancy. For more information, please see the MotherToBaby fact sheet Paternal Exposures at https://mothertobaby.org/fact-sheets/paternal-exposures-pregnancy/pdf/.*

* Section Updated May 2020

Selected References:

  • Bateman BT, et al. 2016. Late pregnancy β Blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics; 138(3). pii:e20160731.
  • Caton AR, et al. 2009. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations.  Hypertension; 54(1):63-70.
  • Chan WS, et al. 2010. Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. Hypertens Pregnancy. 29(3):271-83.
  • Davis RL, et al. 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf.; 20(2):138-45.
  • Firoz T, et al. 2014.Community Level Interventions for Pre-eclampsia (CLIP) Working Group. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 121(10):1210-8.
  • Leitz B, et al.  1983. Secretion of labetalol in breastmilk of lactating women. Fed Proc. 42:378.
  • Lunell NO et al.  1985.  Transfer of labetalol into amniotic fluid and breast milk in lactating women.  Eur J Clin Pharmacol. 28:597-599Michael CA.  1979. Use of labetalol in the treatment of severe hypertension during pregnancy.  Br J Clin Pharmacol. 8 (Suppl 2):211S-2115S.
  • Pasker-de Jong PC, et al. 2010. Antihypertensive treatment during pregnancy and functional development at primary school age in a historical cohort study. BJOG. 117(9):1080-6.
  • Riant P, et al.  1986.  High plasma protein binding as a parameter in the selection of betablockers for lactating women.  Biochem Pharmacol. 35:4579-4581.
  • Ruys TP, et al. 2014. Cardiac medication during pregnancy, data from the ROPAC. Int J Cardiol. 15;177(1):124-8.
  • Tanaka K, et al. 2016. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J; 80(10):2221-6.
  • Van Zutphen AR, et al.   Maternal hypertension, medication use, and hypospadias in the National Birth Defects Prevention Study.  Obstet Gynecol. 123:309-317.
  • Xie RH, et al. 2014. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. Eur J Obstet Gynecol Reprod Biol. 175:124-8.
  • Xie RH, et al. 2014. Beta-blockers increase the risk of being born small for gestational age or of being institutionalised during infancy. BJOG. 121(9):1090-6.

View PDF Fact Sheet

Related Fact Sheets

  • ACE Inhibitors
  • Atenolol (Tenormin®)
  • Beta Blockers
  • Clonidine
  • Lisinopril
  • Metoprolol
  • Nifedipine
  • Propranolol

Footer

           

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Asthma
  • Coronavirus (COVID-19)
  • Crohn’s Disease
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Juvenile Idiopathic Arthritis
  • Multiple Sclerosis
  • Pertussis/Tdap vaccine (“Whopping Cough” vaccine)
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists
OTIS Logo

OTIS National Office
5034A Thoroughbred Lane
Brentwood, TN 37027

Copyright © 2021 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^